- call +1-201-465-4211
- email sales@mrinsights.biz
COPD drugs is a medicine used to treatment chronic obstructive pulmonary disease, such as bronchodilators, pde-4 inhibitors， steroids, combination therapies, etc.
Scope of the Report:
This report studies the COPD Drugs market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the COPD Drugs market by product type and applications/end industries.
One of the emerging trends propelling the growth prospects for this market is the augmented focus and use of combination therapies to treat COPD. Combination therapies are increasingly becoming the preferred choice of treatment as they have better efficacy than monotherapy drugs.
The bronchodilators segment is one of the fastest growing segments of the COPD drugs market. Bronchodilators help relax bronchial muscles resulting in normal breathing. These drugs can be categorized into three types, namely beta-sympathomimetic, anticholinergics, and xanthine derivatives.
The global COPD Drugs market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of COPD Drugs.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Pfizer
Novartis
GlaxoSmithKline
Merck
Abbott Laboratories
Boehringer Ingelheim
AstraZeneca
Roche Holding AG
Teva Pharmaceutical Industries
Vectura Group
Mylan NV
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Bronchodilators
PDE-4 Inhibitors
Steroids
Combination Therapies
Others
Market Segment by Applications, can be divided into
Hospitals
Clinics
Others
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 COPD Drugs Market Overview
1.1 Product Overview and Scope of COPD Drugs
1.2 Classification of COPD Drugs by Types
1.2.1 Global COPD Drugs Revenue Comparison by Types (2017-2023)
1.2.2 Global COPD Drugs Revenue Market Share by Types in 2017
1.2.3 Bronchodilators
1.2.4 PDE-4 Inhibitors
1.2.5 Steroids
1.2.6 Combination Therapies
1.2.7 Others
1.3 Global COPD Drugs Market by Application
1.3.1 Global COPD Drugs Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global COPD Drugs Market by Regions
1.4.1 Global COPD Drugs Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) COPD Drugs Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) COPD Drugs Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) COPD Drugs Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) COPD Drugs Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) COPD Drugs Status and Prospect (2013-2023)
1.5 Global Market Size of COPD Drugs (2013-2023)
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Business Overview
2.1.2 COPD Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Pfizer COPD Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.2 Novartis
2.2.1 Business Overview
2.2.2 COPD Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Novartis COPD Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.3 GlaxoSmithKline
2.3.1 Business Overview
2.3.2 COPD Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 GlaxoSmithKline COPD Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.4 Merck
2.4.1 Business Overview
2.4.2 COPD Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Merck COPD Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.5 Abbott Laboratories
2.5.1 Business Overview
2.5.2 COPD Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Abbott Laboratories COPD Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.6 Boehringer Ingelheim
2.6.1 Business Overview
2.6.2 COPD Drugs Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Boehringer Ingelheim COPD Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.7 AstraZeneca
2.7.1 Business Overview
2.7.2 COPD Drugs Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 AstraZeneca COPD Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.8 Roche Holding AG
2.8.1 Business Overview
2.8.2 COPD Drugs Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Roche Holding AG COPD Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.9 Teva Pharmaceutical Industries
2.9.1 Business Overview
2.9.2 COPD Drugs Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Teva Pharmaceutical Industries COPD Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.10 Vectura Group
2.10.1 Business Overview
2.10.2 COPD Drugs Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Vectura Group COPD Drugs Revenue, Gross Margin and Market Share (2016-2017)
2.11 Mylan NV
2.11.1 Business Overview
2.11.2 COPD Drugs Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Mylan NV COPD Drugs Revenue, Gross Margin and Market Share (2016-2017)
3 Global COPD Drugs Market Competition, by Players
3.1 Global COPD Drugs Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 COPD Drugs Players Market Share
3.2.2 Top 10 COPD Drugs Players Market Share
3.3 Market Competition Trend
4 Global COPD Drugs Market Size by Regions
4.1 Global COPD Drugs Revenue and Market Share by Regions
4.2 North America COPD Drugs Revenue and Growth Rate (2013-2018)
4.3 Europe COPD Drugs Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific COPD Drugs Revenue and Growth Rate (2013-2018)
4.5 South America COPD Drugs Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa COPD Drugs Revenue and Growth Rate (2013-2018)
5 North America COPD Drugs Revenue by Countries
5.1 North America COPD Drugs Revenue by Countries (2013-2018)
5.2 USA COPD Drugs Revenue and Growth Rate (2013-2018)
5.3 Canada COPD Drugs Revenue and Growth Rate (2013-2018)
5.4 Mexico COPD Drugs Revenue and Growth Rate (2013-2018)
6 Europe COPD Drugs Revenue by Countries
6.1 Europe COPD Drugs Revenue by Countries (2013-2018)
6.2 Germany COPD Drugs Revenue and Growth Rate (2013-2018)
6.3 UK COPD Drugs Revenue and Growth Rate (2013-2018)
6.4 France COPD Drugs Revenue and Growth Rate (2013-2018)
6.5 Russia COPD Drugs Revenue and Growth Rate (2013-2018)
6.6 Italy COPD Drugs Revenue and Growth Rate (2013-2018)
7 Asia-Pacific COPD Drugs Revenue by Countries
7.1 Asia-Pacific COPD Drugs Revenue by Countries (2013-2018)
7.2 China COPD Drugs Revenue and Growth Rate (2013-2018)
7.3 Japan COPD Drugs Revenue and Growth Rate (2013-2018)
7.4 Korea COPD Drugs Revenue and Growth Rate (2013-2018)
7.5 India COPD Drugs Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia COPD Drugs Revenue and Growth Rate (2013-2018)
8 South America COPD Drugs Revenue by Countries
8.1 South America COPD Drugs Revenue by Countries (2013-2018)
8.2 Brazil COPD Drugs Revenue and Growth Rate (2013-2018)
8.3 Argentina COPD Drugs Revenue and Growth Rate (2013-2018)
8.4 Colombia COPD Drugs Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue COPD Drugs by Countries
9.1 Middle East and Africa COPD Drugs Revenue by Countries (2013-2018)
9.2 Saudi Arabia COPD Drugs Revenue and Growth Rate (2013-2018)
9.3 UAE COPD Drugs Revenue and Growth Rate (2013-2018)
9.4 Egypt COPD Drugs Revenue and Growth Rate (2013-2018)
9.5 Nigeria COPD Drugs Revenue and Growth Rate (2013-2018)
9.6 South Africa COPD Drugs Revenue and Growth Rate (2013-2018)
10 Global COPD Drugs Market Segment by Type
10.1 Global COPD Drugs Revenue and Market Share by Type (2013-2018)
10.2 Global COPD Drugs Market Forecast by Type (2018-2023)
10.3 Bronchodilators Revenue Growth Rate (2013-2023)
10.4 PDE-4 Inhibitors Revenue Growth Rate (2013-2023)
10.5 Steroids Revenue Growth Rate (2013-2023)
10.6 Combination Therapies Revenue Growth Rate (2013-2023)
10.7 Others Revenue Growth Rate (2013-2023)
11 Global COPD Drugs Market Segment by Application
11.1 Global COPD Drugs Revenue Market Share by Application (2013-2018)
11.2 COPD Drugs Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Clinics Revenue Growth (2013-2018)
11.5 Others Revenue Growth (2013-2018)
12 Global COPD Drugs Market Size Forecast (2018-2023)
12.1 Global COPD Drugs Market Size Forecast (2018-2023)
12.2 Global COPD Drugs Market Forecast by Regions (2018-2023)
12.3 North America COPD Drugs Revenue Market Forecast (2018-2023)
12.4 Europe COPD Drugs Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific COPD Drugs Revenue Market Forecast (2018-2023)
12.6 South America COPD Drugs Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa COPD Drugs Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure COPD Drugs Picture
Table Product Specifications of COPD Drugs
Table Global COPD Drugs and Revenue (Million USD) Market Split by Product Type
Figure Glob
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
